About our Drug Discovery Webinar on Molecular Glues

Join leading experts in drug discovery for a part 2 of molecular glues. This session will dive straight into case studies, uncovering key biological insights and novel chemical approaches that enabled progression from early hits to clinical?candidate. Attendees will gain valuable lessons to inform future research in the evolving field of molecular glue degraders.

For those seeking foundational context on molecular glues, watch Part 1 on demand, which introduces key concepts and mechanisms in targeted protein degradation.

Register to watch our webinar on-demand

You can ask your own questions of our experts.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State

Email(Required)

Thank you for registering to watch our on-demand webinar. By submitting this form, you consent to the collection and processing of your personal data by Pharmaron in accordance with our Privacy Policy. You may be contacted by email following your webinar viewing regarding any questions you may have, as well as relevant services and updates. You can unsubscribe or withdraw your consent at any time.

Agenda:

Attendees will gain a comprehensive understanding of:

CK1α degrader discovery
Key insights on novel hit finding assays for molecular glues
Future perspectives and emerging technologies

Meet our Speakers

Moderated by:

Amy Brown – Biologist, Drug Discovery Services at Pharmaron

Amy is the Biology Project Lead in the Integrated Drug Discovery team at Pharmaron and brings 20 years’ experience and leadership in cell biology, biochemistry, and drug discovery. Before joining Pharmaron in 2023, Amy was at Bicycle Therapeutics, where, for 12 years, she provided scientific leadership across the organization, including: platform technology development; internal Bicycle? toxin conjugate projects from hit ID to IND enabling activities; and collaborations in a variety of therapeutic areas. Before Bicycle Therapeutics, Amy was at Pfizer developing cell-based functional assays across a range of therapeutic areas. She completed an industrial placement at Organon Laboratories as part of her Biochemistry with Industry BSc. Hons, at The University of Leeds.

Speakers:

Bora Lee – Head of Business Development at Pin Therapeutics

Bora Lee is the Head of Business Development at Pin Therapeutics, joining the company in April 2025. She brings 10 years of experience in business development within the biotech industry. Bora specializes in licensing-in and licensing-out strategies, portfolio shaping and transaction execution across discovery through clinical stages.

Before Pin Therapeutics, she led cross-functional initiatives spanning business development, pharmacological research, product development, and intellectual property strategy within emerging biotech ventures. Her therapeutic focus includes immuno-oncology and anti-inflammatory programs, where she has sourced and negotiated collaborations that accelerate preclinical validation and translational progress.

She holds a Ph.D. in Pharmacology from Busan National University, an M.S. in Public Policy from Seoul National University and a B.S. in Business Administration from Seoul National University.

Maxime Couturier – Senior Research Scientist at AstraZeneca

Maxime Couturier completed a doctorate focused on enzymology at the University of Cambridge. In 2021 he joined the Biochemical Assay Development group in AstraZeneca to work on their oncology portfolio. He has a strong interest in protein-protein interaction and targeted protein degradation. Maxime also champions the application of innovative technologies, especially automation and AI, to drug discovery and assay development.

Chris Wellaway – Associate Director, Medicinal Chemistry, Drug Discovery at Pharmaron

Chris Wellaway is a medicinal chemist who joined Pharmaron in June 2022 as an associate director. Prior to this, he spent 17 years at GSK and completed his PhD at the University of Strathclyde. Over his time in the sector, Chris has led molecular glue and PROTAC projects and worked on a range of target classes including E3 ligases, kinases, bromodomains and GPCRs and using various routes of administration. He has experience in phenotypic screening and target identification, hit identification (e.g. fragments and DEL), lead discovery and lead optimisation. Chris particularly enjoys applying contemporary approaches to drug discovery including machine learning and direct to biology, and has a keen interest in PROTACs and molecular glues.